Suppr超能文献

2019冠状病毒病疫苗接种后非严重不良反应的相关因素:德国908,869例门诊疫苗接种队列研究

Factors Associated with Non-Severe Adverse Reactions after Vaccination against SARS-CoV-2: A Cohort Study of 908,869 Outpatient Vaccinations in Germany.

作者信息

Loosen Sven H, Bohlken Jens, Weber Kerstin, Konrad Marcel, Luedde Tom, Roderburg Christoph, Kostev Karel

机构信息

Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.

Institut für Sozialmedizin, Arbeitsmedizin und Public Health (ISAP), Medical Faculty, University of Leipzig, 04103 Leipzig, Germany.

出版信息

Vaccines (Basel). 2022 Apr 6;10(4):566. doi: 10.3390/vaccines10040566.

Abstract

BACKGROUND

Vaccination against SARS-CoV-2 significantly reduces the transmissibility of the virus and the likelihood of a severe course of COVID-19, and is thus a critical component in overcoming the current pandemic. The factors associated with adverse reactions after vaccination against SARS-CoV-2 have not yet been sufficiently evaluated.

METHODS

We used the Disease Analyzer database (IQVIA) to identify 531,468 individuals who received a total of 908,869 SARS-CoV-2 vaccinations in 827 general practices in Germany between April and September 2021. Cox regression models were used to analyze the frequency of vaccination-related side effects reported within 14 days after SARS-CoV-2 vaccination, as well as subjects' demographic characteristics and comorbidities.

RESULTS

The total number of side effects documented was 28,287 (3.1% of all vaccinations). Pain in the limb (24.3%), fatigue (21.0%), dizziness (17.9%), joint pain (15.7%), fever (9.5%), nausea (7.5%), and myalgia (6.4%) were the most common side effects documented among the 12,575 vaccinations with definite side effects. In the multivariate regression analysis, young age was associated with much higher odds of reported side effects (OR: 4.45, OR: 3.50, OR: 2.89). In addition, pre-existing comorbidities such as dementia (OR: 1.54), somatoform disorder (OR: 1.53), anxiety disorder (OR: 1.43), depression (OR: 1.37), chronic respiratory tract disease (OR: 1.27), hypertension (OR: 1.20), and obesity (1.14) significantly increased the odds of side effects. Finally, the male sex was associated with increased odds of reported side effects (OR: 1.17).

CONCLUSION

Our study, based on a large outpatient database from Germany, identified young age, male sex, and pre-existing comorbidities such as dementia, somatoform disorders, anxiety disorders, and depression as factors associated with vaccine-related adverse events diagnosed in GP practices. These data could help to identify subgroups needing particular advice and care in the context of SARS-CoV-2 vaccinations.

摘要

背景

接种针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的疫苗可显著降低该病毒的传播性以及感染新型冠状病毒肺炎(COVID-19)后出现重症病程的可能性,因此是战胜当前疫情的关键组成部分。接种SARS-CoV-2疫苗后出现不良反应的相关因素尚未得到充分评估。

方法

我们使用疾病分析器数据库(艾昆纬公司),在德国827家普通诊所中识别出531468名个体,他们在2021年4月至9月期间共接种了908869剂SARS-CoV-2疫苗。采用Cox回归模型分析SARS-CoV-2疫苗接种后14天内报告的疫苗相关副作用的发生频率,以及受试者的人口统计学特征和合并症。

结果

记录的副作用总数为28287例(占所有接种疫苗的3.1%)。在12575例有明确副作用的疫苗接种中,肢体疼痛(24.3%)、疲劳(21.0%)、头晕(17.9%)、关节疼痛(15.7%)、发热(9.5%)、恶心(7.5%)和肌痛(6.4%)是最常见的副作用。在多变量回归分析中,年轻与报告副作用的几率高得多相关(比值比:4.45、比值比:3.50、比值比:2.89)。此外,痴呆(比值比:1.54)、躯体形式障碍(比值比:1.53)、焦虑症(比值比:1.43)、抑郁症(比值比:1.37)、慢性呼吸道疾病(比值比:1.27)、高血压(比值比:1.20)和肥胖症(1.14)等既往合并症显著增加了出现副作用的几率。最后,男性与报告副作用的几率增加相关(比值比:1.17)。

结论

我们基于德国一个大型门诊数据库开展的研究,确定了年轻、男性以及痴呆、躯体形式障碍、焦虑症和抑郁症等既往合并症是普通诊所中诊断出的与疫苗相关不良事件相关的因素。这些数据有助于识别在SARS-CoV-2疫苗接种背景下需要特别建议和护理的亚组人群。

相似文献

6
Pattern of self-reported adverse events related to COVID-19 vaccines in Saudi Arabia: A nationwide study.
Front Public Health. 2023 Feb 23;11:1043696. doi: 10.3389/fpubh.2023.1043696. eCollection 2023.
7
Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
JAMA Netw Open. 2022 Aug 1;5(8):e2226236. doi: 10.1001/jamanetworkopen.2022.26236.
8
Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study.
Vaccine. 2023 Jun 29;41(29):4267-4273. doi: 10.1016/j.vaccine.2023.05.067. Epub 2023 May 29.

引用本文的文献

2
Mental symptoms in post-COVID syndrome and post-COVID-19 vaccination syndrome: results of a representative population survey.
Front Public Health. 2025 Aug 4;13:1623757. doi: 10.3389/fpubh.2025.1623757. eCollection 2025.
5
Health and Well-Being through COVID-19 Vaccination: Physical, Oral, and Psychological Effects.
Int J Environ Res Public Health. 2023 Feb 10;20(4):3117. doi: 10.3390/ijerph20043117.
6
Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature.
Front Immunol. 2023 Jan 30;14:1078736. doi: 10.3389/fimmu.2023.1078736. eCollection 2023.
8
Vaccine Vigilance System: Considerations on the Effectiveness of Vigilance Data Use in COVID-19 Vaccination.
Vaccines (Basel). 2022 Dec 10;10(12):2115. doi: 10.3390/vaccines10122115.
9
Association between lifestyle and COVID-19 vaccination: A national cross-sectional study.
Front Public Health. 2022 Oct 11;10:918743. doi: 10.3389/fpubh.2022.918743. eCollection 2022.

本文引用的文献

2
Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-analysis.
JAMA Netw Open. 2022 Jan 4;5(1):e2143955. doi: 10.1001/jamanetworkopen.2021.43955.
3
Investigation of the prevalence of non-COVID-19 infectious diseases during the COVID-19 pandemic.
Public Health. 2022 Feb;203:53-57. doi: 10.1016/j.puhe.2021.12.006. Epub 2021 Dec 11.
5
Estimating COVID-19 Infections, Hospitalizations, and Deaths Following the US Vaccination Campaigns During the Pandemic.
JAMA Netw Open. 2022 Jan 4;5(1):e2142725. doi: 10.1001/jamanetworkopen.2021.42725.
6
Demographic and clinical characteristics of primary care patients vaccinated against COVID-19 in spring 2021.
Int J Clin Pharmacol Ther. 2022 Mar;60(3):136-139. doi: 10.5414/CP204178.
7
Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination.
JAMA Netw Open. 2021 Dec 1;4(12):e2140364. doi: 10.1001/jamanetworkopen.2021.40364.
8
Nocebo affects after COVID-19 vaccination.
Lancet Reg Health Eur. 2022 Jan;12:100273. doi: 10.1016/j.lanepe.2021.100273. Epub 2021 Nov 29.
10
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
N Engl J Med. 2021 Dec 16;385(25):2348-2360. doi: 10.1056/NEJMoa2105290. Epub 2021 Sep 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验